The COPD Pipeline XXX.
作者信息
Gross Nicholas
机构信息
Stritch-Loyola School of Medicine, Maywood, Illinois.
出版信息
Chronic Obstr Pulm Dis. 2015 Dec 14;3(1):498-502. doi: 10.15326/jcopdf.3.1.2015.0181.
Abstract
摘要
相似文献
1
The COPD Pipeline XXX.慢性阻塞性肺疾病研发管线XXX。
Chronic Obstr Pulm Dis. 2015 Dec 14;3(1):498-502. doi: 10.15326/jcopdf.3.1.2015.0181.
2
Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.用于治疗慢性阻塞性肺疾病的磷酸二酯酶4抑制剂：现有药物及研发中药物综述
Expert Opin Investig Drugs. 2015;24(12):1597-611. doi: 10.1517/13543784.2015.1094054. Epub 2015 Sep 30.
3
CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration.CHF6001 I：一种新型的高效且选择性的磷酸二酯酶4抑制剂，具有强大的抗炎活性，适用于肺部局部给药。
J Pharmacol Exp Ther. 2015 Mar;352(3):559-67. doi: 10.1124/jpet.114.220541. Epub 2015 Jan 9.
4
Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD.吸入性磷酸二酯酶 4 抑制剂 GSK256066 在中度 COPD 中的安全性和耐受性。
Pulm Pharmacol Ther. 2013 Oct;26(5):588-95. doi: 10.1016/j.pupt.2013.05.004. Epub 2013 May 21.
5
Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.双重 PDE3 和 PDE4 抑制剂 RPL554 在健康志愿者以及哮喘或慢性阻塞性肺疾病患者中的疗效和安全性：四项临床试验的结果。
Lancet Respir Med. 2013 Nov;1(9):714-27. doi: 10.1016/S2213-2600(13)70187-5. Epub 2013 Oct 25.
6
The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.选择性CXCR2拮抗剂口服AZD5069在中重度慢性阻塞性肺疾病患者中的安全性和耐受性
Pulm Pharmacol Ther. 2015 Apr;31:36-41. doi: 10.1016/j.pupt.2015.02.001. Epub 2015 Feb 11.
7
Tetomilast: new promise for phosphodiesterase-4 inhibitors?替托莫司他：磷酸二酯酶-4 抑制剂的新希望？
Expert Opin Investig Drugs. 2012 Dec;21(12):1845-9. doi: 10.1517/13543784.2012.732065. Epub 2012 Oct 8.
8
Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways.双重磷酸二酯酶（PDE）3/4抑制剂RPL554与格隆溴铵在人离体支气管和小气道上相互作用的药理学特征
Pulm Pharmacol Ther. 2015 Jun;32:15-23. doi: 10.1016/j.pupt.2015.03.007. Epub 2015 Apr 18.
9
In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor.体内评价 GSK256066，一种高亲和力的吸入型磷酸二酯酶 4 抑制剂。
J Pharmacol Exp Ther. 2011 Apr;337(1):137-44. doi: 10.1124/jpet.110.173641. Epub 2011 Jan 4.
10
The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD.在 COPD 中双重磷酸二酯酶 3 和 4 抑制剂 RPL554 的短期支气管扩张作用。
Eur Respir J. 2018 Nov 1;52(5). doi: 10.1183/13993003.01074-2018. Print 2018 Nov.
本文引用的文献
1
New developments in inhaler devices within pharmaceutical companies: A systematic review of the impact on clinical outcomes and patient preferences.制药公司吸入器装置的新进展：对临床结果和患者偏好影响的系统评价
Respir Med. 2015 Nov;109(11):1430-8. doi: 10.1016/j.rmed.2015.09.013. Epub 2015 Sep 30.
2
The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.一种选择性CXCR2拮抗剂（AZD5069）对人体血液中性粒细胞计数和固有免疫功能的影响。
Br J Clin Pharmacol. 2015 Dec;80(6):1324-36. doi: 10.1111/bcp.12724. Epub 2015 Oct 2.
3
The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.选择性CXCR2拮抗剂口服AZD5069在中重度慢性阻塞性肺疾病患者中的安全性和耐受性
Pulm Pharmacol Ther. 2015 Apr;31:36-41. doi: 10.1016/j.pupt.2015.02.001. Epub 2015 Feb 11.
4
CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration.CHF6001 I：一种新型的高效且选择性的磷酸二酯酶4抑制剂，具有强大的抗炎活性，适用于肺部局部给药。
J Pharmacol Exp Ther. 2015 Mar;352(3):559-67. doi: 10.1124/jpet.114.220541. Epub 2015 Jan 9.
5
Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.用于治疗哮喘和慢性阻塞性肺疾病的磷酸二酯酶抑制剂。
Int Arch Allergy Immunol. 2014;165(3):152-64. doi: 10.1159/000368800. Epub 2014 Dec 20.
6
Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial.他达拉非在慢性阻塞性肺疾病患者中的应用：一项随机、双盲、平行分组、安慰剂对照试验。
Lancet Respir Med. 2014 Apr;2(4):293-300. doi: 10.1016/S2213-2600(14)70013-X. Epub 2014 Mar 5.
7
Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.双重 PDE3 和 PDE4 抑制剂 RPL554 在健康志愿者以及哮喘或慢性阻塞性肺疾病患者中的疗效和安全性：四项临床试验的结果。
Lancet Respir Med. 2013 Nov;1(9):714-27. doi: 10.1016/S2213-2600(13)70187-5. Epub 2013 Oct 25.
8
Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD.吸入性磷酸二酯酶 4 抑制剂 GSK256066 在中度 COPD 中的安全性和耐受性。
Pulm Pharmacol Ther. 2013 Oct;26(5):588-95. doi: 10.1016/j.pupt.2013.05.004. Epub 2013 May 21.
9
Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial.西地那非治疗慢性阻塞性肺疾病：一项随机交叉试验。
COPD. 2012 Jun;9(3):268-75. doi: 10.3109/15412555.2011.651180. Epub 2012 Feb 23.
10
GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization.GSK256066，一种对磷酸二酯酶 4 具有极高亲和力和选择性的抑制剂，适合通过吸入给药：体外、动力学和体内特征。
J Pharmacol Exp Ther. 2011 Apr;337(1):145-54. doi: 10.1124/jpet.110.173690. Epub 2011 Jan 4.
Zotero 插件